|
Online Database of Chemicals from Around the World | Search | Submit | Advertise | |
Home >> Chemical Listing >> Relacorilant>> Market Analysis Reports |
Market Analysis Reports of Relacorilant |
|
Cushing Syndrome - Pipeline Insight, 2021 ... that use in the US. Relacorilant: Corcept Therapeutics Relacorilant is a non-steroidal, ... hormone receptors. Corcept is studying relacorilant as a potential treatment for a ... ovarian and pancreatic cancer. Relacorilant is proprietary to Corcept and is ... Adrenocortical Carcinoma - Pipeline Insight, 2021 ... Carcinoma Emerging Drugs Relacorilant: Corcept Therapeutics Relacorilant is a non-steroidal, selective ... cortisol levels are high. Relacorilant does not bind to the ... hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety ... Glucocorticoid receptor antagonists - Pipeline Insight, 2022 ... Antagonist Emerging Drugs Relacorilant: Corcept Therapeutics Relacorilant is a non-steroidal, selective ... hormone receptors. Corcept is studying relacorilant in a variety of serious disorders, ... syndrome and pancreatic cancer. Relacorilant has received orphan ... Cushing's Syndrome - Pipeline Review, H1 2018 Cushing's Syndrome - Pipeline Review, H1 2018 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cushing's Syndrome - Pipeline Review, H1 2018, provides an overview of the Cushing's Syndrome (Metabolic Disorders) ... Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical ... Cushing's Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major Cushing's syndrome markets reached a value of US$ 385.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 831.7 Million by 2034, exhibiting a growth rate (CAGR) of 7.25% during 2024-2034. The Cushing's syndrome market ... Corcept Therapeutics Inc (CORT) - Financial and Strategic SWOT Analysis Review ... . Corcept’s major pipeline products include relacorilant for endogenous cushing syndrome; miricorilant ... |